As a pioneer in particle analysis, we are revolutionizing the industry with breakthrough developments and creating an innovative, efficient process that increases quality, safety and cost effectiveness.
We enable faster medicinal development and ensure that both the time and expense in medicinal development can be significantly reduced – while simultaneously increasing quality, production and patient safety.
Bionter’s Executive Team
Bionter’s management team consists of renowned experts in the field of biopharmaceutical industry and particle testing, holding both research and entrepreneurial backgrounds. Together with our collaboration partners, we are working on the idea of improving drug development and quality control. With current as well as future developments within the bioprocess workflow, we aim at making a significant contribution to patient safety and to improve human health.
Founder and CEO of Bionter. He holds a Ph.D. in pharmaceutical sciences and has a long record of inventing and developing innovative devices in the pharmaceutical sector.
CEO & Board Member at ten23 health. He is a pharmacist by training and holds a Ph.D. in pharmacology and toxicology.
Reinhard Vogt is an experienced C-level leader and former Executive Vice President at Sartorius. Vogt holds in-depth knowledge of customer needs, technology, sales and production in the Biotech sector.
Since March 2021, Marc Funk has been CEO of Recipharm, a contract manufacturer and developer for the pharmaceutical industry. Prior to that, Funk held C-level positions at Lonza.
Professor John Carpenter of the University of Denver, Colorado, supports Bionter as one of the world’s leading scientists in particle testing. Dr. Carpenter is an expert in the field of protein aggregation.
What we believe in
Bionter is based on three simple values. We share them among ourselves and those we partner and do business with.